Skip to main content
In stock|Cellular Therapy (CAR-T)

Zamtocabtagene Autoleucel

Oncology TypeHematologic (Lymphoma)
Drug Class / MechanismDual-Targeting Autologous CAR-T, CD19 x CD20
No Image
Description

Zamtocabtagene Autoleucel is classified as a Dual-Targeting Autologous CAR-T, CD19 x CD20, sourced for use within our Cellular Therapy (CAR-T) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryCellular Therapy (CAR-T)
Oncology TypeHematologic (Lymphoma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3